Indication

Cerebral thromboembolism prevention in patient at high risk of gastric ulcer

Cerebral thromboembolism prevention in a patient at high risk of gastric ulcer refers to the prophylactic management of individuals requiring antiplatelet therapy for vascular protection who simultaneously face an elevated vulnerability to mucosal injury and gastrointestinal bleeding. Read more about Cerebral thromboembolism prevention in patient at high risk of gastric ulcer

4 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Cerebral thromboembolism prevention in patient at high risk of gastric ulcer therapies.

Showing 1–4 of 4 drugs

YOSPRALA (aspirin/omeprazole)

MYOCARDIAL INFARCTION PREVENTION IN PATIENT WITH ANGINA PECTORIS AND WITH HIGH GASTRIC ULCER RISK·+3
LEHIGH VALLEY T

YOSPRALA (aspirin/omeprazole)

MYOCARDIAL INFARCTION PREVENTION IN PATIENT WITH ANGINA PECTORIS AND WITH HIGH GASTRIC ULCER RISK·+3
INNOVIDA PHARMA

YOSPRALA (aspirin/omeprazole)

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES·MYOCARDIAL INFARCTION PREVENTION IN PATIENT WITH ANGINA PECTORIS AND WITH HIGH GASTRIC ULCER RISK·+3
PHARMACEUTIKA,
Filter & compare in the drug finder →Opens the drug finder with Cerebral thromboembolism prevention in patient at high risk of gastric ulcer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Cerebral thromboembolism prevention in patient at high risk of gastric ulcer.

Cerebral thromboembolism prevention in a patient at high risk of gastric ulcer refers to the prophylactic management of individuals requiring antiplatelet therapy for vascular protection who simultaneously face an elevated vulnerability to mucosal injury and gastrointestinal bleeding.

In this population, vulnerable cerebral vasculature is threatened by arterial thrombosis or cardiogenic emboli that can occlude intracranial vessels, precipitating ischemic stroke or transient ischemic attacks.

Concurrently, underlying gastrointestinal risk factors—such as advanced age, concurrent ulcerogenic medications, or a prior peptic ulcer—compromise the protective gastric epithelial barrier, leaving the stomach mucosa susceptible to acid-induced erosion and hemorrhage exacerbated by antithrombotic therapy.

This clinical state represents a delicate therapeutic balance between mitigating neurovascular ischemic damage and preventing severe upper gastrointestinal ulceration.

Personalize your experience

Follow Cerebral thromboembolism prevention in patient at high risk of gastric ulcer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it